50 results about "Hypertriglyceridemia" patented technology

Described are RNAi agents, compositions that include RNAi agents, and methods for dual inhibition of an Apolipoprotein C-III (APOC3) and Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene. The APOC3-PCSK9 RNAi agents disclosed herein inhibit the expression of an APOC3 and a PCSK9 gene. Pharmaceutical compositions that include one or more APOC3-PCSK9 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to hepatic cells, in vivo, provides for inhibition of APOC3 and / or PCSK9 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including hypertriglyceridemia and hypercholesterolemia.

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

The invention provides a quadruple plasma blood purification device and purification method. The quadruple plasma blood purification device comprises a primary plasma separator, a secondary plasma separator, a perfusion device and a dialyzer, the inlet of the primary plasma separator is connected with the artery of a patient; an inlet of the secondary plasma separator is connected with the primary plasma separator; an inlet of the perfusion device is connected with the secondary plasma separator; and the dialyzer is respectively connected with the perfusion device and the primary plasma separator. According to the technology, only one-time operation is needed for treatment for 6-12 hours, multiple operations are not needed, meanwhile, the core pathogenesis of hypertriglyceridemia, cytokine storm sepsis, internal environment disorder and renal insufficiency which cause pancreatitis is solved, the treatment time is saved to a great extent, the risk that the illness state develops to death is reduced, and the treatment cost is reduced. The clinical effective treatment rate is improved; in addition, only one set of equipment is needed, and the device has the advantages of low cost, simplicity and convenience in operation, low time, manpower and financial resource consumption, high treatment efficiency and the like.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The present disclosure relates to methods of treating, preventing or managing cardiovascular and / or metabolic disorders selected from the group consisting of hypercholesteremia, dyslipidemia, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes and obesity in a human subject in need thereof by administering a human FGF21 protein variant.

25HC3S choline and crystalline 25HC3S choline are described in the present application. Further disclosed herein are pharmaceutical formulations of 25HC3S choline (e.g., containing crystalline 25HC3S choline) and methods of using the pharmaceutical formulations to treat or prevent diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesteremia, hypertriglyceridemia, and the like. Methods of treating fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus associated growth, and conditions associated with fat accumulation and inflammation are provided. Also provided herein are methods of making 25HC3S, including crystalline 25HC3S choline.

This disclosure provides a vaccine including a peptide with the amino acid sequence of SEQ ID NO:1; a nucleotide having the sequence of SEQ ID NO:2; or a ribonucleotide having the sequence of SEQ ID NO:3. In certain embodiments, the vaccine further comprises a buffer and / or an adjuvant.

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

The present invention relates to pharmaceutical composition(s) comprising particles comprising one or more compounds which are inhibitors of microsomal triglyceride transfer protein and / or apolipoprotein B (Apo B) secretion, wherein at least 50% of the particles are characterized by a volume particle fraction less than 10 μm, more preferably less than 5 μm, more preferably less than 2.5 μm. The pharmaceutical composition can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.

The invention provides an application of dimethyl fumarate in preparation of a medicine for treating hypertriglyceridemia type acute pancreatitis. Experiments prove that the dimethyl fumarate can treat the hypertriglyceridemia acute pancreatitis, and specifically, the dimethyl fumarate can relieve pancreatic tissue edema of the hypertriglyceridemia acute pancreatitis, relieve pancreatitis infiltration, relieve pancreatic acinus necrosis and the like. The invention provides a new strategy for treating hypertriglyceridemia acute pancreatitis, and has a good clinical application prospect.

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, capable of inhibiting the expression of a mitochondrial amidoxime reducing component 1 (MARC1) gene. Also disclosed are pharmaceutical compositions comprising the MARC1 RNAi agent and methods of using the same. In some embodiments, the MARC1 RNAi agents disclosed herein can be conjugated to targeting ligands, including ligands comprising N-acetyl-galactosamine, to facilitate delivery to hepatocytes. Delivery of the MARC1 RNAi agent in vivo provides inhibition of MARC1 gene expression. RNAi agents may be used in methods of treating diseases, disorders or conditions mediated in part by MARC1 gene expression, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1 related diseases.

The present invention provides a method for preparing an animal model of insulin resistance and abnormal glucose metabolism caused by mild to moderate hypertriglyceridemia, by injecting poloxamer 407 solution into the mouse peritoneal cavity at a dose of 25-100 mg per kilogram of mouse, administering the drug once every other day for 12 consecutive weeks, and continuously monitoring blood lipid and blood glucose levels. The preferred dose of the present invention is 75 mg per kilogram of mouse. The present invention also provides the use of the animal model in screening and preparing drugs for treating insulin resistance and abnormal glucose metabolism caused by mild to moderate hypertriglyceridemia. The present invention simulates insulin resistance and abnormal glucose metabolism directly caused by mild to moderate hypertriglyceridemia. Compared with traditional high-fat diets or gene knockout models, triglyceride levels are precisely regulated by chemical intervention, avoiding factors such as obesity and inflammation and the risk of genetic manipulation, and having high controllability and efficiency.

The present invention provides the use of pyruvate in the treatment of lipodystrophy syndrome, belonging to the technical field of endocrine and metabolic disease treatment. This invention proposes for the first time the use of pyruvate, such as sodium pyruvate and potassium pyruvate, in the treatment of lipodystrophy syndrome. It has been found that pyruvate can restore atrophic adipose tissue and improve the progression of diabetic complications and acute pancreatitis associated with hypertriglyceridemia, thereby increasing patient survival and improving overall prognosis.

This invention discloses a method for establishing an improved mouse model of postprandial hypertriglyceridemia, belonging to the field of model construction technology. The key technical points are as follows: the method includes the following steps: obtaining a predetermined number of mouse models, which are then divided into a control group and a model group; administering gavage to both the model group and the control group for 120 minutes; sampling the mice in the model group and the control group after step S2, obtaining samples from both groups; and detecting glucose and lipid-related biochemical indicators, serum SOD, and MDA levels in the samples from both groups. In this invention, a mouse model of hypertriglyceridemia simulating the postprandial dietary state in humans is established through a combination of glucose and lipid administration via gavage. This will provide a research foundation for traditional Chinese medicine research on postprandial hypertriglyceridemia and related glucose and lipid metabolic diseases, and can also provide a model reference for the evaluation of lipid-lowering and hypoglycemic drugs and the development of health products.

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

The present invention provides an iRNA composition that affects the cleavage of the RNA transcript of the ANGPTL3 gene, which is mediated by the RNA-induced silence complex (RISC). The ANGPTL3 may be in a cell, e.g., in a subject, e.g., in a cell in the body of a person. The invention also provides methods of using the iRNA compositions of the invention for inhibiting the expression of the ANGPTL3 gene and / or for treating a subject that would benefit from inhibition or reduction of the expression of the ANGPTL3 gene, such as a subject experiencing or susceptible to dysregulation of lipid metabolism, such as a subject who would benefit from inhibition or reduction of the expression of the ANGPTL3 gene. Such as a subject suffering from or susceptible to hyperlipidemia or hypertriglyceridemia.

Prenylated tetrahydroquinolines and quinolines and pharmaceutical compositions comprising the same. Prenylated tetrahydroquinoline and quinolines and pharmaceutical compositions comprising the same, for use in the prevention and / or treatment of peroxisome proliferator-activated receptor (PPAR)-mediated diseases such as metabolic syndrome, type 2 diabetes mellitus, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, dyslipidemic atherosclerosis, metabolic dysfunction- associated fatty liver disease (MAFLD), cardiovascular disease, cardiometabolic disease, neurodegenerative disease, Friedreich's ataxia, Parkinson's disease, multiple sclerosis, Alzheimer's disease, autoimmune disease, rheumatoid arthritis, autoimmune thyroid disease, dermatological disease, and cancer.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and / or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.

The invention discloses application of aspidopterys obcordata extract in preparation of a medicine for preventing and / or treating obesity. Experiments prove that the traditional Chinese medicine composition has the effects of remarkably reducing the weight, the in-vivo fat content, the body fat rate and the Lee's index of an obesity model mouse and effectively reducing triglyceride in serum, can be used for treating obesity, particularly treating obesity combined with hypertriglyceridemia, and has a good clinical application prospect.

The invention relates to a home management method and system for a patient with hypertriglyceridemia acute pancreatitis, and belongs to the technical field of data analysis. The method comprises the following steps: acquiring auxiliary analysis data of the patient; forming multi-modal sequence data in a time dimension based on the auxiliary analysis data; encoding the multi-modal sequence data based on a time sequence Transform of an attention mechanism, and generating a multi-modal feature vector; inputting the multi-modal feature vector into a risk prediction model, and outputting a deterioration risk probability of the patient; and outputting the health guidance of the patient based on the multi-modal feature vector. The multi-modal data is captured through an attention mechanism, the risk probability is quantified according to the multi-modal data, the potential deterioration risk can be perceived in the early stage, the recurrence and illness worsening risks are remarkably reduced, the health guidance is generated based on the individualized features of the patient, the health guidance is more suitable for the actual life of the patient, and the patient experience is improved. And the management participation and compliance of the patient are further improved.

The invention discloses a pharmaceutical composition for treating chronic kidney disease, belongs to the field of pharmaceutical preparations in the technical field of medicines, and aims to solve the clinical requirements of patients with chronic kidney disease on dyslipidemia, especially hypertriglyceridemia, and the problem that lipid deposition is aggravated due to long-term use of existing statins. The invention provides a solution taking puerarin as a core active component. The weight content of puerarin in the pharmaceutical composition is 5.2%-100%, and the preparation method comprises the following steps: puerarin and an excipient are mixed in proportion and then are subjected to a wet granulation process to form particles, the wet granulation process adopts a hydroxypropyl methylcellulose aqueous solution with the concentration of 2%-5% as an adhesive, and the granulation time is 10-15 minutes; the pharmaceutical composition is suitable for treating chronic nephropathy and improving dyslipidemia of patients by regulating and controlling the synergistic effect of puerarin content and preparation process parameters, and is especially suitable for cases with reduction of glomerular filtration rate along with increase of triglyceride.

The invention provides a double-layer tablet containing ezetimibe and fenofibrate. The double-layer tablet comprises an ezetimibe quick release layer and a fenofibrate slow release layer, the ezetimibe quick-release layer comprises ezetimibe, a quick-release layer filler, a quick-release layer surfactant, a quick-release layer adhesive, a quick-release layer disintegrating agent and a quick-release layer lubricant; the fenofibrate sustained-release layer comprises fenofibrate, a sustained-release layer filler, a sustained-release layer disintegrating agent, a sustained-release layer adhesive, a sustained-release layer solubilizer, a sustained-release layer sustained-release framework material and a sustained-release layer lubricant. The invention also provides a preparation method of the double-layer tablet. The double-layer tablet provided by the invention can be used for clinical treatment of hypercholesterolemia, hypertriglyceridemia and mixed dyslipidemia, the levels of triglyceride, total cholesterol and LDL-C are comprehensively reduced, the level of HDL-C is increased, and the occurrence rate of adverse reactions is relatively low.

The invention discloses a traditional Chinese medicine composition for treating mild and moderate hypertriglyceridemia, and belongs to the technical field of prevention and treatment of hypertriglyceridemia. The traditional Chinese medicine composition consists of the following components in parts by weight: 6-15 parts of broadleaf holly leaf, 3-10 parts of rhizoma acori graminei, 3-10 parts of turmeric, 6-15 parts of hawthorn and 3-10 parts of lotus leaf. The traditional Chinese medicine composition can effectively reduce the high triglyceride level of serum of a patient, helps the serum to recover to a normal value, also has a very good regulation and control effect on other blood fat indexes, can also improve intestinal flora ecology, alleviate the fatty liver degree of the patient, and helps the patient to recover to a health level in multiple dimensions. The traditional Chinese medicine composition has a very good treatment effect on light and medium hypertriglyceridemia patients who do not reach the western medicine medication standard, is simple in components, is prepared from medicinal and edible materials, has no side effect, and is suitable for long-term administration.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit mitochondrial amidoxime reducing component 1 (MARC1) gene expression. Also disclosed are pharmaceutical compositions that include MARC1 RNAi agents and methods of use thereof. The MARC1 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the MARC1 RNAi agents in vivo provides for inhibition of MARC1 gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by MARC1 gene expression, including nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1-related disease.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and / or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.

The present disclosure relates to methods of treating, preventing, or managing a cardiovascular and / or metabolic disorder in a human subject in need thereof by administering a human FGF21 protein variant, wherein the metabolic and / or cardiovascular disorder is selected from hypercholesterolemia, dyslipidemia, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes, and obesity.

ApoE mimetic peptides of 8-17 amino acids long including the ApoE receptor binding region or a portion thereof, and one or more covalent linkages joining at least two non-contiguous amino acids of the peptide are provided. Methods of treating dyslipidemic disorders, such as hypertriglyceridemia or hypercholesterolemia, or viral infection using the peptides are also provided.

This invention belongs to the field of biomedical technology, specifically relating to an isoflavone compound, its preparation method, and its application. This compound is derived from *Rotenoporosis capillaris* (a type of vine). Derris eriocarpa The stem of *Derris fusiforme* was analyzed using 1D and 2D nuclear magnetic resonance (NMR) spectra (1H NMR, 1C NMR, and high-resolution mass spectrometry), and its structural formula is shown below: Chemical name: 5-hydroxy-6-(2"-hydroxy-3"-methylbut-3"-enyl)-3-(4'-hydroxyphenyl)-7-methoxyisoflavone. Screening using the Sci-finder database revealed that this compound is a novel isoflavone, isolated for the first time from *Derris fusiforme*. Lipid-lowering activity experiments showed that at the same drug concentration (25 μg / mL) as the positive control, it significantly reduced intracellular total cholesterol and triglyceride levels. p <0.001). Therefore, this novel isoflavone compound can be used to prepare drugs, health products, functional foods, or special medical foods for the prevention or treatment of hypertriglyceridemia, hyperlipidemia, obesity, or metabolic syndrome.